enGene Therapeutics (ENGN) Non-Current Assets (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Non-Current Assets of $37.5 million for Q2 2026, down 2.98% year-over-year from $38.7 million in Q2 2025, and down 21.66% quarter-over-quarter from $47.9 million in Q1 2026.
enGene Therapeutics (ENGN) Non-Current Assets (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Non-Current Assets for 5 consecutive years, with $37.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 2.98% year-over-year to $37.5 million; the TTM figure through Apr 2026 stood at $139.7 million (down 17.94% YoY), while the FY2025 annual figure was $20.1 million, down 68.54% from the prior year.
- Non-Current Assets slipped to $37.5 million in Q2 2026 per ENGN's latest filing, from $47.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $63.8 million in Q4 2024 and bottomed at $1.3 million in Q4 2022.
- Historically, Non-Current Assets has averaged $26.7 million across 5 years, with a median of $27.2 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 4100.86% — and 2025, when it sank 68.54%.
- enGene Therapeutics' Non-Current Assets stood at $1.3 million in 2022, then rose by 14.56% to $1.5 million in 2023, then soared by 4100.86% to $63.8 million in 2024, then tumbled by 68.54% to $20.1 million in 2025, then surged by 86.9% to $37.5 million in 2026.
- Business Quant data shows ENGN's Non-Current Assets at $37.5 million in Q2 2026, $47.9 million in Q1 2026, and $20.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 37.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 37.52 Mn |
| Jan 31, 2026 | 47.90 Mn |
| Oct 31, 2025 | 20.08 Mn |
| Jul 31, 2025 | 34.24 Mn |
| Apr 30, 2025 | 38.68 Mn |
| Jan 31, 2025 | 63.61 Mn |
| Oct 31, 2024 | 63.81 Mn |
| Jul 31, 2024 | 4.19 Mn |
| Apr 30, 2024 | 3.92 Mn |
| Jan 31, 2024 | 3.84 Mn |
| Oct 31, 2023 | 1.52 Mn |
| Oct 31, 2022 | 1.33 Mn |